News Breaks |
|
|
| October 16, 2012 |
| 07:34 EDT |  | GILD, BMY, ABT | Gilead shares should advance on upcoming data, says RBC Capital
RBC Capital believes that data released by Gilead competitors Abbott (ABT) and Bristol-Myers (BMY) doesn't change the outlook for Gilead, as the firm thinks that the latter company still has the best opportunity in HCV. The firm expects Gilead to report good combo data at AASLD, pushing the stock higher. It maintains an Outperform rating on the shares. |
|
|
News For GILD;ABT;BMY From The Last 14 Days Check below for free stories on GILD;ABT;BMY the last two weeks. |
|
|
| May 21, 2013 |
| 16:51 EDT |  | GILD | Gilead's sofosbuvir gets EMA validation, now under assessment
 Subscribe for More Information |
|
| 08:03 EDT | | ABT | Abbott announces CE Mark for coronary drug eluting stent
Subscribe for More Information |
|
| 07:34 EDT |  | BMY | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT | | BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 07:34 EDT | | GILD | UBS to host a conference
Subscribe for More Information |
|
| 06:30 EDT | | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT |  | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. |
| |
| May 17, 2013 |
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT | | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information |
|
| 08:55 EDT | | BMY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT | | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
|
| May 15, 2013 |
| 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information |
|
| 11:28 EDT | | BMY | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
| |
|
|
|
|
